Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $12M Series X financing bringing the total round to $45M. Participants include New Leaf Venture Partners, Hunt BioVentures, Yasuda Enterprise Development, Baker Brothers Investments, Tullis Dickerson and Four Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.